Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study

Prim Care Diabetes. 2014 Jul;8(2):111-7. doi: 10.1016/j.pcd.2013.07.005. Epub 2013 Aug 14.

Abstract

Aims: Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens.

Methods: A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30.

Results: 1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001).

Conclusions: 24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.

Keywords: A(1)chieve; Basal-bolus insulin regimen; Biphasic insulin aspart; Type 2 diabetes.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Africa, Northern
  • Aged
  • Asia
  • Biomarkers / blood
  • Biphasic Insulins / administration & dosage*
  • Biphasic Insulins / adverse effects
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Administration Schedule
  • Drug Substitution*
  • Female
  • Glycated Hemoglobin A / metabolism*
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / chemically induced
  • Hypoglycemic Agents / administration & dosage*
  • Hypoglycemic Agents / adverse effects
  • Injections
  • Insulin Aspart / administration & dosage*
  • Insulin Aspart / adverse effects
  • Insulin Glargine
  • Insulin, Isophane / administration & dosage*
  • Insulin, Isophane / adverse effects
  • Insulin, Long-Acting / administration & dosage
  • Latin America
  • Male
  • Middle Aged
  • Middle East
  • Quality of Life
  • Russia
  • Time Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Biphasic Insulins
  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • hemoglobin A1c protein, human
  • insulin aspart, insulin aspart protamine drug combination 30:70
  • Insulin Glargine
  • Insulin, Isophane
  • Insulin Aspart